Ovalbumin (OVA; grade V) was purchased from Seikagaku Co., Tokyo, Japan. Short ragweed pollen (RW) was obtained from ICN Biomedicals Inc. (Aurora, OH) and bovine serum albumin (BSA, fraction V), phorbol 12-myristate 13-acetate (PMA), and ionomycin from Sigma-Aldrich (St. Louis, MO). Thirty-eight 15-mer OVA peptides that overlap 5 amino acids were synthesized according to the multipin method (Peptide Institute, Inc., Osaka, Japan). OVA peptide 323-339 was synthesized by solid-phase chemistry using t-butyloxycarbonyl derivatives of the amino acids and purified by HPLC to at least 95% purity (Funakoshi, Tokyo, Japan). 5-(and-6)-Carboxyfluorescein diacetate sucinimidyl ester (CFSE) was purchased from Molecular Probes (Eugene, OR); antibodies against CD3 (G4.18), CD8 (OX-8), CD25 (IL-2 receptor α chain, OX-39), RT1B (rat major histocompatibility complex [MHC] class II equivalent to I-A, OX-6), RT1D (rat MHC class II equivalent to I-E, OX-17), and streptavidin-phycoerythrin from BD-PharMingen (San Diego, CA); anti-CD4 (OX-38) from Caltag (Burlingame, CA); anti-CD45RA (anti-B cell, OX-33) from Cederlane (Hornby, Ontario, Canada); anti-CD68 (anti-monocyte and macrophage, ED-1) from Serotec (Oxford, UK); anti-major basic protein (MBP) from Biodesign International (Saco, ME); anti-Lck (clone 3A5) and anti-phospho-tyrosine (4G10) from Santa Cruz Biotechnology (Santa Cruz, CA); and anti-FITC (F4/1) from Neomarkers (Fremont, CA). KJ1–26, which recognizes transgenic TCR specific to OVA, was used to detect T cells derived from DO11.10 mice. Anti-phosphatidyl inositol-3-kinase (PI3K) p85 was purchased from Upstate Biotechnology (Lake Placid, NY) and protein G Sepharose from Amersham Pharmacia Biotech (Uppsala, Sweden). All antibodies used in immunohistochemistry were biotin-labeled, apart from anti-MBP, anti CD-68, and anti-FITC, which were unlabeled.